|
|
|
Biotechnology company Vybion Inc. said Wednesday it will sell its recombinant protein business to Meridian Biosciences Inc., which makes and markets diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases.
Full Coverage:
Vybion Signs Agreement in Principle to Sell Line of Recombinant Proteins to Meridian Bioscience,...
Vybion, Inc., an Ithaca-based biotechnology company, today announced that it has executed a letter of intent to sell its recombinant protein business to Meridian Bioscience, Inc. (NASDAQ: VIVO). The planned transaction, which both Vybion and Meridian expect will be completed within the next 60...
Vybion Signs Agreement in Principle to Sell Line of Recombinant Proteins to Meridian Bioscience,...
Vybion Signs Agreement in Principle to Sell Line of Recombinant Proteins to Meridian Bioscience, Inc. Vybion Signs Agreement in Principle to Sell Line of Recombinant Proteins to Meridian Bioscience, Inc.ITHACA, N.Y.NY-VYBION Vybion, Inc., an Ithaca-based biotechnology company, today announced...
Meridian Signs Agreement in Principle to Acquire Line of Recombinant Proteins From Vybion, Inc.
Posted on: Tuesday, 13 May 2008, 15:00 CDT Meridian Bioscience, Inc. Cincinnati, Ohio (NASDAQ: VIVO) today announced it has executed a letter of intent to acquire a line of infectious disease recombinant proteins and cardiac antigens from Vybion, Inc. The purchase price includes cash and future...
Meridian Bioscience to buy line of recombinant proteins from Vybion
SAN FRANCISCO (Thomson Financial) - Meridian Bioscience Inc. said Tuesday it executed a letter of intent to acquire a line of infectious disease recombinant proteins and cardiac antigens from Vybion Inc. Financial terms weren't disclosed. The purchase price includes cash and future royalties...
Meridian Signs Agreement in Principle to Acquire Line of Recombinant Proteins from Vybion, Inc.
Meridian Bioscience, Inc. Cincinnati, Ohio (NASDAQ: VIVO) today announced it has executed a letter of intent to acquire a line of infectious disease recombinant proteins and cardiac antigens from Vybion, Inc. The purchase price includes cash and future royalties based on net sales of the acquired...
Meridian Signs Agreement in Principle to Acquire Line of Recombinant Proteins from Vybion, Inc.
News source: Business Wire Meridian Bioscience, Inc. Cincinnati, Ohio today announced it has executed a letter of intent to acquire a line of infectious disease recombinant proteins and cardiac antigens from Vybion, Inc. The purchase price includes cash and future royalties based on net sales of...
Meridian Signs Agreement in Principle to Acquire Line of Recombinant Proteins from Vybion, Inc.
Meridian Bioscience, Inc. Cincinnati, Ohio (NASDAQ: VIVO) today announced it has executed a letter of intent to acquire a line of infectious disease recombinant proteins and cardiac antigens from Vybion, Inc. The purchase price includes cash and future royalties based on net sales of the acquired...
Related categories
United States of America, North America, New York, Ithaca (New York)
International Editions
English - US | English - UK | Deutsch | Française | Español | Português | Italiano | Česká | Русский (Russian) | عربي (Arabic) | 中文（简）(Simplified Chinese)Copyright © 2008 Newstin a.s. All rights reserved. 4.2.5,fe-web-4.2.5;commons-4.2.1;api-4.2.1;fe-4.2.3, 10.10.1.27